Minimally invasive tumor treatment field: the company is the first and only company in China that can provide a relatively complete comprehensive minimally invasive tumor treatment solution. We have successfully developed a series of special equipment for minimally invasive treatment of tumors, covering the main core areas of minimally invasive treatment of tumors, such as internal radiotherapy, radiofrequency ablation, interventional thermochemotherapy, external hyperthermia, immune recovery therapy, and hydrothorax and ascites treatment for advanced tumors. Among them, interventional thermochemotherapy perfusion system and immunotherapy system are original inventions, which have been included in the list of the first recommended equipment in state administration of traditional chinese medicine. After the follow-up development of products such as electromagnetic positioning puncture navigation system and dual-frequency electromagnetic hyperthermia machine is completed, the company will cover the main technical fields of minimally invasive tumor treatment with its own equipment. At present, the company's minimally invasive tumor treatment equipment covers 155 tertiary hospitals (coverage rate reaches 12.57%) and 172 secondary hospitals (coverage rate reaches 2.64%).

Huashen group

The company's primary liver cancer drug I [13 1i] Metuximab Injection (Likatine) is a national first-class innovative drug, and it is the first gene drug in the world to treat liver cancer with monoclonal antibodies. The company has independent intellectual property rights for the treatment of advanced liver cancer. Cooperate to build three cancer diagnosis and treatment centers.

Hengkang medical treatment

The company invested10.20 billion yuan to acquire 85% of the income right of Red Cross Cancer Clinic15. According to the assets evaluation, 85% of the operating income right of the Red Cross Cancer Clinic in 2005 was 654.38+42 million yuan. 20 12,1-1month, the clinic realized a net income of 3 144 1 ten thousand yuan. In addition, the company and the Red Cross Cancer Hospital intend to entrust the medical management and business development of the cancer diagnosis and treatment center to Yaoyu Company.

Cancer detection related:

Huace detection

Nitrosamine is a strong carcinogen, which can cause tumors in offspring through placenta and milk, and has teratogenic and mutagenic effects. The main focus of the company's successful research and development of 1 1 nitrosamines; Phosphate flame retardants are potentially carcinogenic, teratogenic and neurotoxic, and the company has developed a gas chromatography-mass spectrometry detection method for these five substances; Organochlorine pesticides will cause large-scale and long-term harm to humans and animals, cause endocrine disorders, damage reproductive and immune systems, and induce cancer and nervous system diseases. Therefore, the company has developed 34 detection methods of organochlorine pesticides specified by AAFA, and the above three technologies have reached the international advanced level.

Xilong technology

It is planned to invest 20 million yuan to acquire 75% equity of New World Bio, and develop tumor detection reagents, total antioxidant status (TAS) detection kits (FRAP method) and various biochemical reagents, which have a certain market scale in the in vitro diagnostic reagent industry; If the acquisition is completed, the company will enter the biochemical reagent industry, providing new growth points for future development.

Taige medicine

The company mainly provides clinical trial technical services, data management, statistical analysis, registration and other clinical research services for pharmaceutical product research and development. As a clinical trial CR O (contract research institution) enterprise, the company has a high level of clinical research, and is one of the few CRO local enterprises capable of conducting international multi-center trials in China. It has always been in a leading position in the clinical research field of innovative drugs, and has 35 clinical research experiences of first-class new drugs, involving hepatitis, tumor, endocrine, cardiovascular and cerebrovascular diseases, AIDS and other fields.

Rongzhilian

Huada Science and Technology cooperated with START Company of South Texas to launch the San Antonio Genome Project. On September 20th/30th/Kloc-0th/2nd, Shenzhen Huada Gene Technology Service Co., Ltd. (hereinafter referred to as "Huada Science and Technology"), the world's largest gene research institution, and South Texas Accelerated Research and Therapeutics officially announced that they would jointly launch and promote the San Antonio/Kloc-0th/000 Cancer Genome Project (SA/. The project creatively combines genetic variation with clinical characterization, which will further promote the development of personalized medicine with drug-specific markers. The project funds of SA 1kCGP are all donated by private individuals, and the whole genome data of 10 common cancers obtained in the research will be made public to researchers around the world free of charge. Rongzhilian (002642) semi-annual report shows that it used its own funds of 65,438 yuan+5 million yuan to participate in Shenzhen Huada Gene Technology Service Co., Ltd. ..

Fosun Pharma

The company invested USD 22.4 million to subscribe for 4,299,400 D series preferred shares of SALADAX Company. After subscription, the company will become its single largest shareholder. Meanwhile, Fosun Chang Zheng, a subsidiary of SALADAX authorized company, has exclusive distribution rights and product manufacturing rights in China. SALADAX has the world's leading detection technology and tumor chemotherapy drug monitoring product portfolio. Through this cooperation, the company's innovative ability in the field of medical diagnosis will be effectively enhanced, and it is expected to launch a biochemical detection platform in China and even the global market, which can detect the concentration of tumor chemotherapy drugs, thus contributing to better analysis of the therapeutic effect of tumor chemotherapy drugs. It is expected that this product line will form a considerable sales scale in China in the future.

Daheng technology

The company's medical equipment has world-class "3DIMRT (Intensity Modulated Radiotherapy System)", leading generation of "3D Radiotherapy Planning System (3DTPS) and Digital Virtual Human Body Technology (VHP)", which is a large-scale comprehensive medical equipment integrating computer technology, image processing technology and radiotherapy equipment. Because the product has indisputable technical advantages, it has been equipped in more than 200 well-known hospitals in China, and its market share ranks first in China.

Cancer vaccine related:

Haixin stock

A national first-class drug independently developed for the treatment of rectal cancer, named "antigen sensitized human dendritic cells (APDC)", is the first national first-class drug independently developed in China and officially approved by the State Food and Drug Administration (SFDA). It is jointly developed by Haixin Biotechnology Company (the company holds 5 1%) and Shanghai Second Military Medical University. Antigen-sensitized human dendritic cells (APDC) developed by Hisense Bio is a new generation of therapeutic tumor vaccine for colorectal cancer. (2065438+July 26th, 2002, APDC project was approved by the State Food and Drug Administration for Phase III clinical trial. )

Watson biological

Holding Shanghai Zerun (holding 50.69%). Shanghai Zerun is in a leading position in the research and development of preventive and therapeutic cervical cancer vaccine (human papillomavirus), and its recombinant human papillomavirus preventive vaccine is the first HPV vaccine developed by eukaryotic expression system and passed clinical trials in China.

Biology of zhifei

The company signed the "HPV vaccine" agreement with Merck, an affiliated company of Merck, stipulating that after the products of the agreement are listed, the company is allowed to distribute exclusively in the agreement area (Chinese mainland area). Merck HPV vaccine (trade name: Jiadaxiu) is the first cancer vaccine in the world and the only cancer vaccine approved for preventing cervical cancer and precancerous lesions of reproductive organs caused by HPV6, 1 1, 16 and 18. At present, it has been listed in 124 countries and regions.

Cancer drugs:

Guonong technology

Huatai Pharmaceutical, a holding subsidiary, plans to expand Penglai production base with a total investment of 265,438+03,480,000 yuan. The scale of the project is 22 million ordinary small-volume injections, 22 million ordinary freeze-dried powder injections and 6.5438+million anti-tumor freeze-dried powder injections. The construction period is planned to be 2.5 years, and the production date is 654.38+0.5 years. In the long run, some products in the project are currently imported from China, and the current market is good and the sales are relatively stable.

Consistent ethnic medicine

Dorazole (35. 19%), an antineoplastic drug developed by Wan Le Pharmaceutical Co., Ltd.

Fengyuan pharmacy

Fengyuan Renzhong Pharmaceutical Co., Ltd., a joint venture between the company and Renzhong Technology (the company holds 60% of the shares), ensures that the new anticancer drug cisplatin implant will be listed before the end of September 2065438+2002; The company invested heavily in research and development of new drugs for adjuvant treatment of cancer.

Tetracyclic organism

The company's main products include recombinant human interleukin-2 (used for comprehensive treatment of malignant tumors such as kidney cancer and malignant melanoma), recombinant human interleukin-2 injection, recombinant human granulocyte stimulating factor injection and recombinant human erythropoietin injection, among which recombinant human interleukin-2 for injection is an industrialized genetic engineering product of the national project "Development, pilot production and clinical application of genetically engineered human interleukin -2"; At present, Beijing Sihuan Bio (0005 18) Pharmaceutical Co., Ltd., which still holds 55% equity, is the earliest enterprise engaged in the research, development and production of genetic engineering drugs and diagnostic reagents in China. Its proprietary technology includes sublingual buccal tablets such as interleukin -2 (used to treat liver cancer), interferon, EPO and G-CSF.

Hainan Haiyao

Bendamoustine, a subsidiary of Haikou Pharmaceutical Factory, is an anti-tumor drug with dual mechanisms of nitrogen mustard and purine analogues. There is no bendamustine listed or imported in China, which belongs to a new class of 3. 1 chemicals. Paclitaxel injection produced by the company is the first listed product in China. Paclitaxel is mainly used in the first-line and second-line treatment of ovarian cancer, breast cancer and non-small cell lung cancer, and also has certain curative effect on head and neck cancer, esophageal cancer, seminoma and recurrent non-Hodgkin's lymphoma, with brand and price advantages.

Changchun high-tech

Changchun Jinsai Pharmaceutical Co., Ltd. (holding 70% of the shares), a subsidiary of the company, is the only national-level genetic engineering drug incubation base among Chinese pharmaceutical enterprises. Its growth hormone series products have ranked first in the country and even in the Asia-Pacific region, becoming a leader in the field of child growth and development treatment, and at the same time establishing a leading position with core competitive advantages in many fields such as burns, assisted reproduction, anti-aging and cancer. Jinsai Pharmaceutical continues to maintain the first market share of auxin in China.

Luopu drugstore

The company holds 98.07% of Baishixin produced by Zhejiang Prokangyu Pharmaceutical Co., Ltd., which is a national second-class anti-tumor drug; In the first half of 20 10, the high-tech industrialization demonstration project of synthesizing D- p-hydroxyphenylglycine by genetic engineering enzyme was included in the national high-tech industrialization demonstration project. Shanxi Datong Development Zone Pharmaceutical Industrial Park (the second park) is engaged in the development and construction of medicine and R&D base. After the project is completed, the estimated production capacity is 654.38+0 billion water injections per year and 20 million freeze-dried powder injections per year. The total investment of the project is 250 million yuan, which is divided into two phases. At present, the company has completed the declaration of four products of cardiovascular and cerebrovascular injection, and is waiting in line at the drug evaluation center for evaluation. At the same time, the preliminary research work of four characteristic tumor injection products was completed.

Peking University medicine

Kangboming Disodium Phosphate (CA4P) and its injection, which the company cooperates with Founder Medical Research Institute, are a kind of vascular targeting drug or endothelial destruction drug. The mechanism is that the blood supply of tumor is quickly interrupted, which leads to the death of tumor due to insufficient oxygen supply and nutritional hunger. It will take about 5-6 years to get the approval of this medicine. Palonosetron hydrochloride is a second generation 5-HT3 receptor antagonist, which is mainly used to treat and prevent acute nausea and vomiting caused by moderate and severe vomiting chemotherapy. Clinically, it is often used as an auxiliary drug for tumors and the prevention and treatment of postoperative nausea and vomiting. After the drug goes on the market, it will have a positive impact on the company's future performance.

China resources Sanjiu

Anhui Jinchan Biochemical Company, 83.68% owned by the company, mainly produces cinobufotalin injection, which can be used for the treatment of advanced tumors, chronic hepatitis B and other diseases.

Huabang healthy

Chongqing Winbond and Chongqing Winbond Sheng Kai, holding subsidiaries of the Company, received the registration documents of "calcium levofolinate Raw Material Medicine" and "calcium levofolinate for Injection" (3. 1 class chemicals) approved and issued by the State Administration of Pharmaceutical Products. Calcium levofolinate for injection is the second drug of Chongqing Winbond in the field of cancer, which has a positive impact on further improving the product line in the field of cancer. Clinical application of calcium levofolinate for injection combined with fluorouracil in adjuvant treatment of gastric cancer and colorectal cancer can prolong the survival time. Calcium levofolinate for injection, as the corresponding isomer of calcium folinate for injection, has obvious advantages in efficacy and safety.

Shuanglu pharmacy

The company was selected as one of the first batch of "10000 Project" key cultivation enterprises in "Beijing Biomedical Industry Leaping Development Project" and Zhongguancun (9. 10+1.34%) National Independent Innovation Demonstration Zone. The company has reserved a number of superior varieties with market potential at home and abroad in the fields of tumor treatment, anti-inflammatory and analgesic, cardiovascular and cerebrovascular diseases and liver diseases, and strives to introduce more than three antibodies and vaccine drugs. Constantly cultivate heavy varieties in the field of liver disease treatment, and strive to become an important enterprise in the field of liver disease treatment in China. The company's main products, such as recombinant human granulocyte colony stimulating factor, interleukin-1 1, asparaginase and anti-tumor products, are gradually entering the markets of Eastern Europe, Asia and South America.

Xinlitai

Establish "Tsinghua University-Xinlitai (002294) Small Molecule Joint R&D Center" with Tsinghua University to improve the screening ability of innovative drugs for major diseases such as cardiovascular and cerebrovascular diseases and anti-tumor diseases, and improve the efficiency of R&D; The production process of the preparation involved in the national 1 innovative drug-alisartan ester was introduced, and the production approval of clopidogrel hydrochloride tablets at 75MG and 300MG and the clinical approval of lercanidipine tablets were obtained.

Zhongsheng pharmacy

Signed a tripartite technical cooperation agreement with Guangdong South China New Drug Creation Center and Sichuan University to develop new drug projects. The three projects developed in the first phase are QU 100 project, WCH-0 16 project and DXZ923 nanometer preparation project.

Essence pharmaceutical

Research and development of the second-generation targeted anti-tumor drug betatinib: The synthetic route of the drug has been opened, the salt and crystal form screening have been completed, a small number of samples have been prepared, and the preliminary quality stability of the raw material drug is being investigated.

Yuheng pharmacy

Gemcitabine hydrochloride-anti-tumor drug: Gemcitabine hydrochloride for injection is an anti-metabolic tumor drug, which is widely used to treat pancreatic cancer and non-small cell lung cancer. There are only three pharmaceutical factories in China: Lilly, Jiangsu Haosen and Yuheng Pharmaceutical (002437).

Laimei pharmacy

The company's core technologies include nano-drug technology of lymphatic targeted therapy, micro-nano dispersion and suspension preparation technology of drugs and preparation technology of sterile raw materials, among which nano-drug technology of lymphatic targeted therapy is at the international leading level; Anti-tumor drugs are mainly nano-carbon suspension injection and fludarabine phosphate for injection, and parenteral nutrition drugs are mainly N(2)-L- alanyl -L- glutamine injection, which fills the gap in China and has great clinical application value. The proportion of anti-tumor drugs in the company's product structure will continue to increase. At present, the company's anti-tumor drugs account for about 20%, and it is expected to surpass anti-infective drugs to reach about 40% within three years. The company's product nano-carbon suspension injection is mainly used as lymphatic tracer. Its appearance as a diagnostic lymphatic tracer fills the gap in China and is the first generic drug of this kind in China. The preparation technology of related products has been protected by national patents, and the company has taken the lead in launching this product in the world. Fludarabine phosphate for injection is suitable for the treatment of patients with B-cell chronic lymphoblastic leukemia (CLL). According to statistics, in the domestic market of fludarabine phosphate for injection, the company's market share is 65,438+00.35%, ranking third in the market.

Anke biotechnology technology

The company plans to introduce anti-tumor drug S- 1 tablet project. S- 1 is a new compound antitumor drug, which is mainly used to treat advanced or metastatic gastric cancer. It is estimated that 20 12 will be put into production, with an annual production capacity of 30 million pieces.

Xiangxue pharmacy

The new drug company has paid $6.5438+0.5 million to KINEX as agreed. It is estimated that it will take more than 5-6 years for KX02 to be developed into a new drug. On June 20 13, KINEX was approved by FDA IND. After submitting and modifying relevant documents, the first phase clinical study of the compound (KX2-36 1) in the United States can be started. At the same time, KINEX will also start the first phase clinical study of KX02 project as planned. KX02 is a lipophilic anti-tumor compound, which can penetrate the blood-brain barrier and its mechanism is clear. Animal experiments show that it can effectively inhibit malignant glioma cells and may develop into an effective new drug for treating brain tumors.

Renfu medicine

Gedian Renfu Pharmaceutical Co., Ltd., which holds 8 1.07% equity, is a professional research and development enterprise engaged in steroid hormone raw materials, fertility regulation drugs and anti-tumor drugs. Shenzhen Xinpeng Bioengineering, which holds 52% of the shares, is developing the internationally leading anti-cancer gene drug project TR- 1, and it is expected to obtain the first-class new drug certificate within 3-5 years.

Taiji group

Four new drugs with independent intellectual property rights have been jointly developed with scientific research institutes: new anticancer drugs, new drugs for diabetes (complications) and new drugs for cardiovascular diseases, of which two have obtained clinical approval, 1 is applying for production approval, and 90 1, 902903904 and 905 new product projects have been independently screened. DXJS, the first new dosage form of antineoplastic drugs at home and abroad, has completed the process research, and the preclinical research has entered a comprehensive summary stage. It is expected that the clinical application will be completed in 20 13.

Jiangsu Wuzhong

Wu Traditional Chinese Medicine, a holding subsidiary, is currently carrying out the project of "R&D and industrialization of recombinant human endostatin injection, a national first-class biological anticancer drug", which is in the stage of applying for phase III clinical research and has independent intellectual property rights. In 2006, it was supported by the national "863" project of non-small cell lung cancer.

Tailong pharmacy

The company decided to take anti-tumor and cardiovascular and cerebrovascular products as the new research and development direction in the next stage. The dosage forms of the products are mainly small-volume injections and freeze-dried powder injections.

Zhongheng group

The company agreed to provide Peking University with no more than 654.38 billion yuan of cooperative scientific research funds in 10 year, and 654.38 billion yuan in the first year, and support it to carry out research on early diagnosis of cancer by single cell sequencing every year according to the research progress and budget. The related research of the project should be combined with the treatment mechanism and direction of related products (such as sorbitan, etc.) of the company. ) to promote the promotion of products.

Haizheng pharmacy

The company is a leading manufacturer of APIs in China and one of the largest production bases of antibiotics and anti-tumor drugs in China. The company's preparation export base project under construction has an annual output of 25 million bottles of cytotoxic antineoplastic drugs for injection, 25 million bottles of freeze-dried powder for injection and 654.38+600 million tablets of solid preparations; The company's gene drug tumor necrosis factor receptor antibody fusion protein has now entered the second phase of clinical trials.

Hengrui pharmacy

L-calcium folinate, a chiral drug with a single enantiomer in our company, can be used to enhance the anti-tumor activity of 5- fluorouracil, mainly treating symptoms related to folic acid antagonism and colon cancer and kidney cancer after high-dose methotrexate treatment; The company ranks first in China in a variety of anti-tumor drugs, three of which are exclusively produced in China. The existing generic drugs oxaliplatin and docetaxel are in the growth stage, and irinotecan is also entering a period of rapid growth. The company should have apatinib mesylate, a molecular targeted anti-tumor drug.

Yabao pharmacy

Freeze-dried powder for injection, such as vindesine sulfate for anti-tumor drug injection.

Kangenbei

The "Recombinant Highly Effective Compound Interferon" developed by Far East Super Laboratory, a wholly-owned subsidiary of Hong Kong Kangenbei (600572) Company, obtained the first-phase clinical trial license in Singapore. The drug is a new unnatural interferon with a brand-new spatial conformation, which can be used for inhibiting virus replication and anti-tumor treatment. Far East Laboratory was registered in British Virgin Islands on June 28th, 2005. Mainly engaged in the research and development of cancer treatment drugs based on recombinant high-efficiency compound interferon (RSIFN-CO) products and technologies.

Baiyi drugstore

The company owns Aidi injection, an anti-tumor traditional Chinese medicine with genetic technology, and obtains VEGI proprietary technology of polypeptide chain products through genetic engineering, which can directly activate different types of immune cells and inhibit or eliminate cancer cells. The research of Aidi injection has reached the genetic level (Aidi injection is the exclusive product of the company). Aidi, the first-line product of the company, is an exclusive variety of anti-tumor traditional Chinese medicine injections, accounting for about 45% of the income. Aidi's sales in tertiary hospitals account for about 80% of the sales of this kind of drugs. Lobplatin is the latest third-generation platinum antineoplastic drug, the only exclusive variety among the top five platinum antineoplastic drugs in China, and it is currently in a high-speed growth period.

Shenqi pharmacy

Guizhou Jinqiao Pharmaceutical, a subsidiary of the company, has passed the new GMP certification, and the publicity period passed yesterday. It is reported that the anticancer drug sodium cantharidate injection passed GMP certification this time. The company holds 92.58% equity of Jinqiao Pharmaceutical, and sodium cantharidate injection is suitable for the treatment of tumors such as primary liver cancer. 20 13 annual report shows that sodium cantharidate injection and related products constitute nearly 20% of the company's main income.

Harbin pharmaceutical co., ltd

The bioengineering company is mainly committed to producing and selling drugs for treating tumors, cardiovascular and cerebrovascular diseases and liver diseases. At present, there are many bioengineered pharmaceutical products such as recombinant human interferon ι-2b for injection (trade name: Lineng), recombinant human erythropoietin injection (trade name: Shedasheng), recombinant human granulocyte stimulating factor injection (trade name: Riyajin) and alprostadil fat emulsion, among which the market share of recombinant human interferon ι-2b for injection and alprostadil injection is in the leading position in China.

Listed companies related to anti-cancer concept in non-pharmaceutical industry:

Zhongzhu holding

Qianjiang Pharmaceutical Co., Ltd., a holding subsidiary, cooperated with TNI Company of the United States to carry out preclinical research on anticancer drugs for cancer of blood and bone marrow hematopoietic system and immune recovery of cancer patients. The pre-clinical trial fee of Qianjiang Pharmaceutical Co., Ltd. is estimated to be 654.38+million yuan. If the clinical approval is not obtained, 80% of the pre-clinical trial fee will be refunded.

Jianfeng group

After the completion of the project, Jianfeng Pharmaceutical, a holding subsidiary, will form a production line with an annual output of 35 tons of cephalosporins, anti-tumor drugs and other raw materials (supporting preparations) and 200 million powder injection production lines. On April 2, 20 10, it was announced that Jianfeng Pharmaceutical Co., Ltd., which holds 99 16% of the company, plans to invest 39 million yuan (in installments) to cooperate with China Pharmaceutical University and its Institute of Pharmaceutical and Chemical Engineering to carry out preclinical research on a new type of anti-tumor drug (DPT).

Lansheng stock

34.65% of Lansheng Guo Jian Pharmaceutical Co., Ltd. and CITIC Pacific jointly invested to establish "Shanghai CITIC Guo Jian Pharmaceutical Co., Ltd.", with Lansheng Guo Jian accounting for 465,438+0.69% and our company accounting for 0.73%. In 2008, the new biological drug "Yisaipu" (recombinant human1kloc-0/tumor necrosis factor receptor-antibody fusion protein for injection) developed by CITIC Guo Jian won the second prize of the National Science and Technology Invention Award, which is the first humanized monoclonal antibody drug in China to truly realize industrialization and marketization. Four 750-liter cell culture production lines have been completed and put into operation smoothly, with an annual production capacity of 4 million mg.

Asia Pacific group

The company takes biological vaccines and anti-tumor drugs as the development direction of new products, and has formed a series of anti-cancer products led by "Shenyi Capsule" and anti-cancer biological missiles. At the same time, new anticancer drugs such as interleukin-1 1 and ginsenoside RG3 injection have been reserved.

Adjuvant treatment of cancer:

Zhendong pharmacy

Yan Shu injection, the core leading product, is an auxiliary drug for cancer treatment, which has the functions of inhibiting cancer pain and bleeding, inhibiting tumor growth, and enhancing efficacy and reducing toxicity by combining radiotherapy and chemotherapy.

Yiling pharmacy

Yiling research institute, a wholly-owned subsidiary of the company, cooperated with Cardiff University to set up a medical research center. The center will carry out in-depth exchanges and cooperation around the target research, clinical application and market resource enjoyment of traditional Chinese medicine. It is found that Yangzhengxiaoji capsule can inhibit tumor angiogenesis, thus inhibiting tumor growth and metastasis. Yangzhengxiaoji capsule is mainly used for adjuvant treatment of tumors, and it is helpful to improve the curative effect of chemotherapy when combined with chemotherapy drugs. Yangzhengxiaoji capsule combined with interventional therapy for primary liver cancer has obvious curative effects in enhancing efficacy, reducing toxicity, enhancing immunity, improving syndromes and improving quality of life.

Heiske

Liaoning Haisike (002653), a subsidiary of the company, obtained the drug registration approval of six national chemicals "methylprednisolone succinate" and "methylprednisolone sodium succinate for injection". Methylprednisolone is one of the most widely used adrenocortical drugs at present, which can be used to treat severe patients in many departments, such as allergic diseases and malignant tumors. Methylprednisolone (injection) is a class B drug in the national medical insurance catalogue. After the drug goes on the market, it will enrich the company's product line and have a positive impact on the company's future performance improvement.

Jinhua stock

Transfer factor oral liquid is used to treat viral infection and autoimmune diseases. At the same time, it can be used for adjuvant treatment of malignant tumor and tumor patients after radiotherapy and chemotherapy.

Pien Tze Huang

Pien Tze Huang (600436) is mainly composed of bezoar, musk, notoginseng and snake gall. Besides treating acute and chronic viral hepatitis, carbuncle and furuncle, innominate swelling, traumatic injury and various inflammations caused by toxic heat and blood stasis, it can also inhibit the growth of cancer cells in digestive system and can be used as an auxiliary anti-tumor drug. The company applied for a research and development patent and was accepted.

Kangyuan pharmacy

Tongan injection produced by Tongan injection is a pure Chinese medicine injection for treating moderate and severe cancer pain, and has independent intellectual property rights. Through effective promotion, the company plans to make it at least partially replace opioid analgesic drugs in a few years and become the first-line variety of cancer pain treatment drugs in China.